JP7857080B2 - 破傷風神経毒素に結合する単一ドメイン抗体 - Google Patents

破傷風神経毒素に結合する単一ドメイン抗体

Info

Publication number
JP7857080B2
JP7857080B2 JP2020545344A JP2020545344A JP7857080B2 JP 7857080 B2 JP7857080 B2 JP 7857080B2 JP 2020545344 A JP2020545344 A JP 2020545344A JP 2020545344 A JP2020545344 A JP 2020545344A JP 7857080 B2 JP7857080 B2 JP 7857080B2
Authority
JP
Japan
Prior art keywords
sda
tent
sdas
binding
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020545344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021516682A (ja
Inventor
スミット, アブラハム ヨハネス デ
マイケル マリー ハームセン,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smivet BV
Original Assignee
Smivet BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smivet BV filed Critical Smivet BV
Publication of JP2021516682A publication Critical patent/JP2021516682A/ja
Priority to JP2023191811A priority Critical patent/JP2024023268A/ja
Application granted granted Critical
Publication of JP7857080B2 publication Critical patent/JP7857080B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020545344A 2018-03-13 2019-03-13 破傷風神経毒素に結合する単一ドメイン抗体 Active JP7857080B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023191811A JP2024023268A (ja) 2018-03-13 2023-11-09 破傷風神経毒素に結合する単一ドメイン抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18161521 2018-03-13
EP18161521.2 2018-03-13
PCT/EP2019/056299 WO2019175250A1 (en) 2018-03-13 2019-03-13 Single domain antibodies binding to tetanus neurotoxin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023191811A Division JP2024023268A (ja) 2018-03-13 2023-11-09 破傷風神経毒素に結合する単一ドメイン抗体

Publications (2)

Publication Number Publication Date
JP2021516682A JP2021516682A (ja) 2021-07-08
JP7857080B2 true JP7857080B2 (ja) 2026-05-12

Family

ID=61691657

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020545344A Active JP7857080B2 (ja) 2018-03-13 2019-03-13 破傷風神経毒素に結合する単一ドメイン抗体
JP2023191811A Pending JP2024023268A (ja) 2018-03-13 2023-11-09 破傷風神経毒素に結合する単一ドメイン抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023191811A Pending JP2024023268A (ja) 2018-03-13 2023-11-09 破傷風神経毒素に結合する単一ドメイン抗体

Country Status (10)

Country Link
US (2) US12054540B2 (cg-RX-API-DMAC7.html)
EP (1) EP3765495A1 (cg-RX-API-DMAC7.html)
JP (2) JP7857080B2 (cg-RX-API-DMAC7.html)
CN (2) CN117964751A (cg-RX-API-DMAC7.html)
AU (2) AU2019233603B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020018563A2 (cg-RX-API-DMAC7.html)
MA (1) MA51996A (cg-RX-API-DMAC7.html)
MX (2) MX2020009507A (cg-RX-API-DMAC7.html)
WO (1) WO2019175250A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202403355B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113248610B (zh) * 2021-05-14 2022-08-16 厦门柏慈生物科技有限公司 白细胞介素2结合分子、其衍生物、试剂盒及其生产方法和用途
AU2022287910A1 (en) * 2021-06-07 2023-12-14 Michael L. MARTINO Rapid recognition based diagnosis and treatment
CN117624360A (zh) * 2022-08-26 2024-03-01 南京融捷康生物科技有限公司 一种抗trem2的单域抗体及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503059A (ja) 1999-06-25 2003-01-28 インペリアル カレッジ オブ サイエンス, テクノロジー アンド メディシン 破傷風毒素ポリペプチド
JP2009524641A (ja) 2006-01-25 2009-07-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 対立遺伝子排除
JP2011504740A (ja) 2007-11-27 2011-02-17 アブリンクス エン.ヴェー. ヘテロ二量体サイトカイン及び/又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド
JP2016528884A (ja) 2013-06-28 2016-09-23 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 細胞において神経毒ポリペプチドの生物活性を決定する手段及び方法
WO2016187594A1 (en) 2015-05-21 2016-11-24 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
JP2017538414A (ja) 2014-12-09 2017-12-28 ニューヨーク・ユニバーシティ クロストリジウム神経毒融合タンパク質、プロペプチド融合体、それらの発現及び使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
EP0698097B1 (en) 1993-04-29 2001-08-16 Unilever N.V. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
EP0739981A1 (en) * 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
AUPS022802A0 (en) * 2002-01-31 2002-02-21 Macfarlane Burnet Institute For Medical Research And Public Health Limited, The Anti-viral compounds
AU2004245429A1 (en) 2003-06-10 2004-12-16 Farallone Holding Bv Binding peptides: methods for their generation and use
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
CN101386648B (zh) * 2008-09-25 2012-05-30 中国人民解放军军事医学科学院微生物流行病研究所 抗b型肉毒神经毒素中和性单克隆抗体、其制备方法及用途
AU2010267963B2 (en) * 2009-07-02 2015-09-24 Merz Pharma Gmbh & Co. Kgaa Neurotoxins exhibiting shortened biological activity
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
SI3339323T1 (sl) * 2010-08-12 2019-12-31 Eli Lilly And Company Protitelesa proti N3PGLU amiloid beta peptidu in njihove uporabe
US9409950B2 (en) 2010-12-23 2016-08-09 Biogen Ma Inc. Linker peptides and polypeptides comprising same
JP6162135B2 (ja) * 2011-11-09 2017-07-12 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 短縮された生物活性を示す神経毒
WO2013110531A1 (en) * 2012-01-23 2013-08-01 Ablynx Nv Sequences directed against hepatocyte growth factor (hgf) and polypeptides comprising the same for the treatment of cancers and/or tumors
WO2013157105A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ5ac特異的ヒト化抗体およびその利用
US10668147B2 (en) * 2015-03-25 2020-06-02 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Anti-CD89 cytotoxic complex

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503059A (ja) 1999-06-25 2003-01-28 インペリアル カレッジ オブ サイエンス, テクノロジー アンド メディシン 破傷風毒素ポリペプチド
JP2009524641A (ja) 2006-01-25 2009-07-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 対立遺伝子排除
JP2011504740A (ja) 2007-11-27 2011-02-17 アブリンクス エン.ヴェー. ヘテロ二量体サイトカイン及び/又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド
JP2016528884A (ja) 2013-06-28 2016-09-23 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 細胞において神経毒ポリペプチドの生物活性を決定する手段及び方法
JP2017538414A (ja) 2014-12-09 2017-12-28 ニューヨーク・ユニバーシティ クロストリジウム神経毒融合タンパク質、プロペプチド融合体、それらの発現及び使用方法
WO2016187594A1 (en) 2015-05-21 2016-11-24 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FEBS Letters, 1997年, Vol.414, pp.521-526
mAbs, 2015年, Vol.7, No.5, pp.820-828

Also Published As

Publication number Publication date
JP2024023268A (ja) 2024-02-21
US20220275066A1 (en) 2022-09-01
AU2019233603B2 (en) 2025-06-26
US12054540B2 (en) 2024-08-06
MX2020009507A (es) 2020-10-22
CN112135840B (zh) 2024-01-23
ZA202403355B (en) 2024-12-18
US20240376185A1 (en) 2024-11-14
MX2025004782A (es) 2025-05-02
JP2021516682A (ja) 2021-07-08
CN112135840A (zh) 2020-12-25
CN117964751A (zh) 2024-05-03
MA51996A (fr) 2021-01-20
BR112020018563A2 (pt) 2020-12-29
EP3765495A1 (en) 2021-01-20
AU2025234234A1 (en) 2025-10-09
WO2019175250A1 (en) 2019-09-19
AU2019233603A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
JP7241731B2 (ja) 血清アルブミン結合剤
US20240376185A1 (en) Tetanus prophylaxis
US9850315B2 (en) Antigen-binding protein directed against epitope in the CH1 domain of human IgG antibodies
US20240132624A1 (en) Polypeptides binding to a specific epitope of the neonatal fc receptor
US20240368250A1 (en) Polypeptides binding to the neonatal fc receptor
US20210347868A1 (en) Anti-synuclein antibodies
US20250129145A1 (en) Bi- and multivalent albumin binders
Rossotti et al. Increasing the potency of neutralizing single-domain antibodies by functionalization with a CD11b/CD18 binding domain
CN113631579B (zh) 组织纤溶酶原激活物抗体及其使用方法
WO2024084203A1 (en) Single domain antibodies binding to albumin
Harmsen et al. Serum immunoglobulin or albumin binding single-domain antibodies that enable tailored half-life extension of biologics in multiple animal species
Traxlmayr et al. Integrin binding human antibody constant domains—Probing the C-terminal structural loops for grafting the RGD motif
WO2025219585A1 (en) Vhh antibodies which bind to canine albumin
JP2025525566A (ja) Cx3cr1結合化合物、その使用及び関連する方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201019

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20201019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220310

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231109

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231114

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260424

R150 Certificate of patent or registration of utility model

Ref document number: 7857080

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150